Sapheon brings in $8.6mm so far through its planned $18.5mm Series B venture round; closes at $19.8mm
Vascular disease device developer Sapheon Inc. has raised $8.6mm through the first closing of its Series B venture round. It issued 4.8mm shares to 33 investors and hopes to bring in $18.5mm when the financing is completed. Aaron Berez, MD, former CEO of Chestnut Medical Technologies, will take a seat on the company’s board. Sapheon is developing the VenaSeal system to close the saphenous vein in cases of venous reflux disease.
- Medical Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com